Ítem
Acceso Abierto

Adalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitis

Mostrar el registro sencillo de la publicación
dc.creatorFabiani, Claudiaspa
dc.creatorCantarini, Lucaspa
dc.creatorTosi, Gian Marcospa
dc.creatorFrediani, Brunospa
dc.creatorHussein Amin, Ranaspa
dc.creatorLa Torre, Francescospa
dc.creatorGupta, Vishalispa
dc.creatorHegazy,Mohamed Tharwatspa
dc.creatorMurthy, Kalpana Babuspa
dc.creatorLopalco, Giuseppespa
dc.creatorMauro, Angelaspa
dc.creatorSota, Jurgenspa
dc.creatorFrancesca Gicchino, Mariaspa
dc.creatorCaggiano, Valeriaspa
dc.creatorChimenti, Maria Solespa
dc.creatorCivino, Adelespa
dc.creatorBernal-Valencia, María Andreaspa
dc.creatorSaboya-Galindo, Paolaspa
dc.creatorEtayari, Halahspa
dc.creatorMejía-Salgado, Germánspa
dc.creatorMinoia, Francescaspa
dc.creatorGentileschi, Stefanospa
dc.creatorFotis, Lamprosspa
dc.creatorVitale, Antoniospa
dc.creatorHashad, Soadspa
dc.creatorDammacco, Rosannaspa
dc.creatorTarsia, Mariaspa
dc.creatorCarreño, Esterspa
dc.creatorFonollosa, Alexspa
dc.creatorMaggio, Maria Cristinaspa
dc.creatorCattalini, Marcospa
dc.creatorLa Bella, Saveriospa
dc.creatorBreda, Lucianaspa
dc.creatorDel Giudice, Emanuelaspa
dc.creatorParoli, Maria Piaspa
dc.creatorRagab, Gaafarspa
dc.creatorCosti, Stefaniaspa
dc.creatorGuerriero, Silvanaspa
dc.creatorde la Torre Cifuentes, Ligia Alejandraspa
dc.creatorGaggiano, Carlaspa
dc.date.accessioned2025-07-21T16:39:21Z
dc.date.available2025-07-21T16:39:21Z
dc.date.created2025-01-01spa
dc.date.issued2025-01-01spa
dc.description.abstractBackground: The study objective was to compare the effectiveness of adalimumab (ADA) in monotherapy and in combination with methotrexate (MTX) for paediatric noninfectious uveitis (NIU). Methods: Registry-based observational study. Children receiving ADA for active uveitis were divided into the ADA monotherapy group (group 1) and the ADA plus MTX combination group (group 2). Results Eighty four children were enrolled (146 eyes): 22 in group 1 (26.2%) and 62 in group 2 (73.8%). ADA effectiveness was complete in 48 children (57.1%), partial in 23 (27.4%) and absent in 4 (5.3%), without any differences across the groups (p?=?0.89). Fewer relapses per 100 PY occurred after ADA treatment both in group 1 (280.0 vs. 23.0, p?=?0.005) and in group 2 (297.9 vs. 86.0, p?<?0.001). The final BCVA was similar between groups 1 and 2 [median 1.0 (IQR 0.3) and 1.0 (IQR 0.3), respectively, p?=?0.55]. A statistically significant steroid-sparing effect was observed in the entire cohort and in group 2 at the 6-month (p?=?0.01 and p?=?0.01), 12-month (p?=?0.02 and p?=?0.02), and last follow-up (p?=?0.045 and p?=?0.045). The estimated ADA retention rate was 97.1% at 12?months, 87.7% at 24?months, and 82.6% at 36?months, without a statistically significant difference among the groups (p?=?0.77). Conclusions: ADA monotherapy could be equally effective as its combination with MTX in both preventing uveitis relapses and preserving visual acuity in paediatric NIU, with comparable retention rates over 36?months of treatment. The steroid-sparing effect of ADA monotherapy warrants further extensive evaluation to define its optimal placement in the therapeutic strategy for paediatric NIU.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1111/ceo.14534spa
dc.identifier.issn1442-6404spa
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/46056
dc.language.isoengspa
dc.publisherJohn Wiley & Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Ophthalmologistsspa
dc.relation.ispartofClinical & Experimental Ophthalmology 2025; 0:1-8spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/ceo.14534spa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accesoAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourceClinical & Experimental Ophthalmologyspa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordOftalmologíaeng
dc.subject.keywordAdalimumabeng
dc.subject.keywordMethotrexateeng
dc.subject.keywordMonotherapyeng
dc.subject.keywordNoninfectious uveitiseng
dc.subject.keywordPaediatric ophthalmologyeng
dc.titleAdalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitisspa
dc.typearticlespa
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersionspa
dc.type.spaArtículo de Investigaciónspa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Adalimumab_Monotherapy_or_Combination_Therapy_With_Methotrexate_in_Paediatric_Uveitis.pdf
Tamaño:
813.9 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos